Skip to content

Optical Tomographic Imaging of Infantile Hemangiomas

Optical Tomographic Imaging of Infantile Hemangiomas

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01673971
Enrollment
15
Registered
2012-08-28
Start date
2012-05-31
Completion date
2018-01-01
Last updated
2018-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile Hemangioma

Keywords

hemangioma

Brief summary

The investigators hypothesize that there are differences between infantile hemangiomas (IH) during the proliferating and involuting phases and in response to medical treatment that can be detected by optical tomography of these hemangiomas.

Detailed description

Infantile hemangiomas (IH) are common vascular growths that frequently arise in infants. The clinical presentation is variable, and some hemangiomas have the potential to cause disfiguring and even lifethreatening complications. While there is no FDA approved treatment for IH, certain medications have been shown to be effective in shrinking the growths. Unfortunately, there is no objective tool to monitor IH or to guide treatment. Such a tool would improve the management of these patients. A new handheld wireless device uses diffuse optical imaging (DOI) technology to measure blood flow characteristics. The device has been used in studies to assess patients with breast cancer. Optical tomography has also been increasingly used to assess neurological function and pathology in newborn infants. The goal of the investigators' study is to assess the utility of DOI for characterizing and monitoring IH. Fifteen IH will be assessed at three points in time as part of this study, comprising two groups: 'Natural History' and 'Treatment'. DOI measurements will be correlated with clinical findings and existing ultrasound measurements of the IH.

Interventions

None listed

Sponsors

Columbia University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 7 Years
Healthy volunteers
No

Inclusion criteria

For the 'Natural History' Cohort, the following inclusion and

Exclusion criteria

apply: INCLUSION CRITERIA: * Infants with IH who present to our practices within the first 2 months of life. * IH of size \> 2 cm in diameter * IH located on area of skin that is accessible to contact by 4x2cm probe. Examples include the lateral face, forehead, scalp, trunk and areas of the extremities not overlying joints. Infants with IH that do not necessitate either medical or surgical intervention at time of presentation.

Design outcomes

Primary

MeasureTime frameDescription
Difference in tissue oxygen saturation (StO2) of hemangioma and normal skin.Up to 2 yearsMeasurements of tissue oxygen saturation (StO2) of hemangioma and normal skin are obtained using a diffuse optical imaging device and are compared at different time points.
Difference in absolute total hemoglobin concentration ([THb]) of hemangioma and normal skin.Up to 2 yearsMeasurements of absolute total hemoglobin concentration (\[THb\]) of hemangioma and normal skin are obtained using a diffuse optical imaging device and are compared at different time points.

Secondary

MeasureTime frameDescription
Difference in absolute total hemoglobin concentration ([THb]) of hemangioma at different time points.Up to 2 yearsMeasurements of absolute total hemoglobin concentration (\[THb\]) of the hemangioma are obtained at different time points and compared.
Difference in tissue oxygen saturation (StO2) of the hemangioma at different time points.Up to 2 yearsMeasurements of tissue oxygen saturation (StO2) of the hemangioma are obtained at different time points and compared.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026